{"id":4397669,"date":"2023-08-25T08:14:00","date_gmt":"2023-08-25T13:14:00","guid":{"rendered":"https:\/\/www.olartemoure.com\/?p=4397669"},"modified":"2023-08-24T22:11:38","modified_gmt":"2023-08-25T03:11:38","slug":"declaration-regarding-dolutegravir","status":"publish","type":"post","link":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/","title":{"rendered":"Declaration of public interest regarding dolutegravir"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; theme_builder_area=&#8221;post_content&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221;][et_pb_row _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; theme_builder_area=&#8221;post_content&#8221; width=&#8221;100%&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; hover_enabled=&#8221;0&#8243; sticky_enabled=&#8221;0&#8243;][et_pb_column _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; type=&#8221;4_4&#8243; theme_builder_area=&#8221;post_content&#8221;][et_pb_text _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; theme_builder_area=&#8221;post_content&#8221; text_font_size=&#8221;1.2em&#8221; text_line_height=&#8221;1.5em&#8221; text_orientation=&#8221;justified&#8221; hover_enabled=&#8221;0&#8243; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p>In June of this year and by means of resolution 881 of 2023, an administrative procedure of declaration of reasons of public interest was initiated to submit the <a href=\"https:\/\/www.olartemoure.com\/patent-families\/\" target=\"_blank\" rel=\"noopener\">patents<\/a> of medicines whose active ingredient is Dolutegravir to compulsory licensing.<\/p>\n<p>During the term established for this purpose, the holder of the patents and other interested third parties submitted comments and requested the decree of certain tests. Likewise, during said term, the Association of Pharmaceutical Research and Development Laboratories (AFIDRO), requested the revocation of the resolution.<\/p>\n<p>Last Friday, August 18, the Interinstitutional Technical Committee (led by the Ministry of Health) issued an order in which it rejects such request for revocation as improper, and makes a decision regarding the request for evidence, in which several of the testimonial and documentary evidence provided by AFIDRO and the patent holder were rejected. The Committee is expected to issue its opinion in the coming weeks.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>An administrative procedure was initiated to submit the patents of medicines whose active ingredient is Dolutegravir to compulsory licensing.<\/p>\n","protected":false},"author":5,"featured_media":4397671,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<!-- wp:divi\/placeholder \/-->","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[8,51,58,59],"tags":[],"class_list":["post-4397669","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-patentes","category-patents","category-newsletter","category-newsletter-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Declaration of public interest regarding dolutegravir - OlarteMoure<\/title>\n<meta name=\"description\" content=\"An administrative procedure was initiated to submit the patents of medicines whose active ingredient is Dolutegravir to compulsory licensing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Declaration of public interest regarding dolutegravir\" \/>\n<meta property=\"og:description\" content=\"An administrative procedure was initiated to submit the patents of medicines whose active ingredient is Dolutegravir to compulsory licensing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/\" \/>\n<meta property=\"og:site_name\" content=\"OlarteMoure | Intellectual Property\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-25T13:14:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/olartemoure.com\/wp-content\/uploads\/2023\/08\/dolutegravir.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1601\" \/>\n\t<meta property=\"og:image:height\" content=\"837\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nicole Diaz\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicole Diaz\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/declaration-regarding-dolutegravir\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/declaration-regarding-dolutegravir\\\/\"},\"author\":{\"name\":\"Nicole Diaz\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/39418ad779f2cd1c62156f11faaf2e31\"},\"headline\":\"Declaration of public interest regarding dolutegravir\",\"datePublished\":\"2023-08-25T13:14:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/declaration-regarding-dolutegravir\\\/\"},\"wordCount\":246,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/declaration-regarding-dolutegravir\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/dolutegravir.jpg\",\"articleSection\":[\"Patentes\",\"Patents\",\"Newsletter\",\"Newsletter\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/declaration-regarding-dolutegravir\\\/\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/declaration-regarding-dolutegravir\\\/\",\"name\":\"Declaration of public interest regarding dolutegravir - OlarteMoure\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/declaration-regarding-dolutegravir\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/declaration-regarding-dolutegravir\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/dolutegravir.jpg\",\"datePublished\":\"2023-08-25T13:14:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/39418ad779f2cd1c62156f11faaf2e31\"},\"description\":\"An administrative procedure was initiated to submit the patents of medicines whose active ingredient is Dolutegravir to compulsory licensing.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/declaration-regarding-dolutegravir\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/olartemoure.com\\\/en\\\/declaration-regarding-dolutegravir\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/declaration-regarding-dolutegravir\\\/#primaryimage\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/dolutegravir.jpg\",\"contentUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/dolutegravir.jpg\",\"width\":1601,\"height\":837,\"caption\":\"dolutegravir\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/declaration-regarding-dolutegravir\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Declaration of public interest regarding dolutegravir\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/\",\"name\":\"OlarteMoure | Intellectual Property\",\"description\":\"Firma especializada en Propiedad Intelectual\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/olartemoure.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/39418ad779f2cd1c62156f11faaf2e31\",\"name\":\"Nicole Diaz\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g\",\"caption\":\"Nicole Diaz\"},\"sameAs\":[\"https:\\\/\\\/www.olartemoure.com\"],\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/author\\\/webmaster\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Declaration of public interest regarding dolutegravir - OlarteMoure","description":"An administrative procedure was initiated to submit the patents of medicines whose active ingredient is Dolutegravir to compulsory licensing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/","og_locale":"en_US","og_type":"article","og_title":"Declaration of public interest regarding dolutegravir","og_description":"An administrative procedure was initiated to submit the patents of medicines whose active ingredient is Dolutegravir to compulsory licensing.","og_url":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/","og_site_name":"OlarteMoure | Intellectual Property","article_published_time":"2023-08-25T13:14:00+00:00","og_image":[{"width":1601,"height":837,"url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2023\/08\/dolutegravir.jpg","type":"image\/jpeg"}],"author":"Nicole Diaz","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicole Diaz","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/#article","isPartOf":{"@id":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/"},"author":{"name":"Nicole Diaz","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/39418ad779f2cd1c62156f11faaf2e31"},"headline":"Declaration of public interest regarding dolutegravir","datePublished":"2023-08-25T13:14:00+00:00","mainEntityOfPage":{"@id":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/"},"wordCount":246,"commentCount":0,"image":{"@id":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2023\/08\/dolutegravir.jpg","articleSection":["Patentes","Patents","Newsletter","Newsletter"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/","url":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/","name":"Declaration of public interest regarding dolutegravir - OlarteMoure","isPartOf":{"@id":"https:\/\/olartemoure.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/#primaryimage"},"image":{"@id":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2023\/08\/dolutegravir.jpg","datePublished":"2023-08-25T13:14:00+00:00","author":{"@id":"https:\/\/olartemoure.com\/#\/schema\/person\/39418ad779f2cd1c62156f11faaf2e31"},"description":"An administrative procedure was initiated to submit the patents of medicines whose active ingredient is Dolutegravir to compulsory licensing.","breadcrumb":{"@id":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/#primaryimage","url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2023\/08\/dolutegravir.jpg","contentUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2023\/08\/dolutegravir.jpg","width":1601,"height":837,"caption":"dolutegravir"},{"@type":"BreadcrumbList","@id":"https:\/\/olartemoure.com\/en\/declaration-regarding-dolutegravir\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/olartemoure.com\/en\/"},{"@type":"ListItem","position":2,"name":"Declaration of public interest regarding dolutegravir"}]},{"@type":"WebSite","@id":"https:\/\/olartemoure.com\/#website","url":"https:\/\/olartemoure.com\/","name":"OlarteMoure | Intellectual Property","description":"Firma especializada en Propiedad Intelectual","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/olartemoure.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/39418ad779f2cd1c62156f11faaf2e31","name":"Nicole Diaz","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g","caption":"Nicole Diaz"},"sameAs":["https:\/\/www.olartemoure.com"],"url":"https:\/\/olartemoure.com\/en\/author\/webmaster\/"}]}},"_links":{"self":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/4397669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/comments?post=4397669"}],"version-history":[{"count":0,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/4397669\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media\/4397671"}],"wp:attachment":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media?parent=4397669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/categories?post=4397669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/tags?post=4397669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}